The inimitable Dr Wendy Osborne delivering a fantastic educational on how to optimally manage R/R Large B cell Lymphoma 👏🏾 ⭐️

Tackling common misconceptions about clinical trials! Hear from our clinical research nurses as they discuss the different contexts in which patients may be offered a clinical trial. 🎧Full episode is now live on Spotify, Amazon Podcasts, and YouTube.

"We were an hour from going bust..." How did Cure Leukaemia overcome one of the toughest moments in our charity's history? Hear CEO James McLaughlin share the story in our latest podcast episode🎙️ 🎧 Available now on Spotify, Amazon Podcasts, and YouTube.

Presented at #ASCO26—frontMIND phase 3. Investigated: tafasitamab lenalidomide and R-CHOP in patients with high-risk aggressive B-cell lymphomas. Findings suggest the intervention represents a potential new first-line treatment for patients with high-risk DLBCL or HGBL. Read more: spkl.io/601776onN

frontMIND Ph3 in newly diagnosed high risk LBCL First data presented #ASCO26 by DrGeorgLenz 🇩🇪 with simultaneous publication @TheLancet Look out for plenary at #EHA2026 kwnsfk27.r.eu-west-1.awstrac…

“Let’s talk Blood Cancer” A fantastic podcast venture from @CureLeukaemia : patient-focused & accessible info. Hopefully digestible & myth-busting! Kudos #AdamJoyce 👏🏾 the host with the most! @act4patients @charliecraddock @NottmBRC @NottmCRF @drpramilak @PaulSherringto7

On #InternationalNursesDay we are delighted to announce our major 3 year funding extension to Accelerating Clinical Trials Ltd, ensuring the continued growth of a national infrastructure dedicated to fast-tracking pioneering treatments for blood cancer patients. "The impact of this partnership is already being felt on the global stage. In 2025, findings from five major clinical trials delivered through the TAP and IMPACT trials networks were selected for presentation at the prestigious American Society of Haematology (ASH) Annual Meeting, highlighting the UK’s leading role in international haematology research." This is only possible thanks to the tireless efforts of our supporters and fundraisers across the globe, to enable Cure Leukaemia to fund Research Nurses and critical clinical trials roles across the UK ❤️ Read the full story at - cureleukaemia.co.uk/news/cur… @act4patients

What is the role of a Clinical Research Nurse?🤔 We’re proud to be funding our incredible Nurses, made possible thanks to the support of the CL Family ❤️ 🎧Full episode is now live on Spotify, Amazon Podcasts, and YouTube.

It’s back! Lymphoma Management 2026. Online and very reasonably priced. As ever a wonderful line up of speakers bringing up to date trial data and clinical insight to optimise the outcome of our patients. Looking forward to welcoming you to the course. lymphoma-action.org.uk/event…

Excellent meeting & great 🇨🇿 group - thank you for the invitation and the Czech hospitality in beautiful Prague! @MarekTrnenyDr

Fascinating perspective & clear messages from @AmandaGoodall1 on the importance physician leadership. A 6 minute listen with @SocietyofHemOnc #SOHOinsider on the why, how & when!

Optimising 1L intensive chemoimmunoRx in PCNSL… Impressive recruitment Ph3 RCT n=326 in a rare & challenging disease Congrats 👏🏾 to study teams in 🇬🇧 🇩🇪 🇮🇹 Now we wait for the data…. @GeraldIllerhaus @LizSchorb @CwynKate @FSchererMD @Jessica_Okosun @UoNPIBeacon @SU2CUK

On #WorldCancerDay, we’re proud to announce a major expansion of our partnership with Flutter Entertainment becoming our first ever global partner. Over the next three years, Flutter’s £3 million commitment will accelerate clinical trials by funding Cure Leukaemia Research Nurses across the UK. This is a continuation of their fundraising efforts, where colleagues have generated more than £2 million since 2023, improving access to potentially lifesaving treatments. Now, the partnership is scaling that impact globally, engaging 29,000 Flutter colleagues across 30 countries through sport, endurance, and community fundraising. Read more about the partnership and what it will deliver here: cureleukaemia.co.uk/news/flu… #DoMore #PositiveImpact

Your weekend listen, sorted 🎧 Have you tuned into Let’s Talk Blood Cancer, The Patients’ Podcast yet? Episodes 1-3 are now live on YouTube, Spotify, and all major podcast platforms. charitytoday.co.uk/cure-leuk…

📘𝘑𝘰𝘪𝘯 𝘶𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘶𝘱𝘤𝘰𝘮𝘪𝘯𝘨 𝘐𝘈𝘊𝘏 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘊𝘭𝘶𝘣: 𝗧𝗮𝗳𝗮𝘀𝗶𝘁𝗮𝗺𝗮𝗯, 𝗹𝗲𝗻𝗮𝗹𝗶𝗱𝗼𝗺𝗶𝗱𝗲, 𝗮𝗻𝗱 𝗿𝗶𝘁𝘂𝘅𝗶𝗺𝗮𝗯 𝗶𝗻 𝗿𝗲𝗹𝗮𝗽𝘀𝗲𝗱 𝗼𝗿 𝗿𝗲𝗳𝗿𝗮𝗰𝘁𝗼𝗿𝘆 𝗳𝗼𝗹𝗹𝗶𝗰𝘂𝗹𝗮𝗿 𝗹𝘆𝗺𝗽𝗵𝗼𝗺𝗮 (𝗶𝗻𝗠𝗜𝗡𝗗): 𝗮 𝗴𝗹𝗼𝗯𝗮𝗹, 𝗽𝗵𝗮𝘀𝗲 𝟯, 𝗿𝗮𝗻𝗱𝗼𝗺𝗶𝘀𝗲𝗱 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗱 𝘁𝗿𝗶𝗮𝗹 𝘸𝘪𝘵𝘩 𝘊𝘩𝘳𝘪𝘴 𝘍𝘰𝘹, 𝘓𝘢𝘶𝘳𝘪𝘦 𝘚𝘦𝘩𝘯 𝘢𝘯𝘥 𝘔𝘰𝘩𝘢𝘮𝘢𝘥 𝘔𝘰𝘩𝘵𝘺 🗓️ 𝘛𝘩𝘶𝘳𝘴𝘥𝘢𝘺, 𝘑𝘢𝘯 29, 2026 ⏰ 6𝘱𝘮 𝘊𝘌𝘛 🎟️ 𝘍𝘙𝘌𝘌 𝘳𝘦𝘨𝘪𝘴𝘵𝘳𝘢𝘵𝘪𝘰𝘯 𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 𝘯𝘰𝘸👉us06web.zoom.us/webinar/regi… @Mohty_EBMT @ProfChrisPFox @SehnLaurie

🎙️ EPISODE 3 — NOW LIVE! Professor @charliecraddock, Founder of Cure Leukaemia, answers the question, "Are we ever going to live in a world without blood cancer?" Search 'Let's Talk Blood Cancer' on Spotify, all major platform platforms, YouTube for the full episode or click here: youtu.be/fiMRDqiOxns

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) ir.genmab.com/news-releases/…

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma investor.incyte.com/news-rel…